Hepatoprotective Effect of Pioglitazone in Cases of Chemotherapy Induced Steatohepatitis
S. Celik, K. Kartal, H. Ozseker, M. Hayran, E. HamalogluOriginal article, no. 1, 2015
Background Objectives: To evaluate the harmful effects of5-floururacil (5-FU) and Irinotecan on the liver and to determinethe role of Pioglitazone in averting liver damage.Methods: Sixty Sprague-Dawley female rats were divided into4 groups. The first group (n=20) was administered 40 mg of5-FU and 40 mg kg of Irinotecan intraperitoneally for 4cycles, while the second group (n=20) received 4 mg kg ofPioglitazone by gastric gavage at 5 days a week for 20 days inaddition to chemotherapy. The third group (n=10) was thesham group; chemotherapy regimen was given as in the firstgroup. In addition, normal saline was given daily for 20 daysby gastric gavage. The fourth group (n=10) was only given astandard diet as a control group. Then, blood samples werestudied for the evaluation of alanine aminotransferase (AST)and alanine aminotransferase (ALT) levels. And left liverlobes of rats were taken for pathological analysis.Results: Although short-term chemotherapy was administered,aminotransferase (AST) and alanine aminotransferase (ALT)levels were found to be significantly higher in the first andthird groups compared to the others (p 0.0001). No significant difference was determined between the second and thecontrol group. Pioglitazone reduced the adverse metaboliceffects of chemotherapy on the liver, but had no effect on thehistopathological changes.Conclusion: short-term CT causes metabolic disruption inhepatocytes, but not relevant with CASH. Preventivetreatments like Pioglitazone should be used more carefully.
